Dec 08, 2021 Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer
Sep 22, 2021 Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Jul 08, 2021 Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
May 12, 2021 Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
May 06, 2021 Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
Mar 09, 2021 Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights
Mar 04, 2021 Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference